Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

- PMLiVE

Keytruda is UK’s first early-access medicine

Merck’s melanoma therapy accepted under the UK’s EAMS

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

- PMLiVE

AZ and University of Texas to collaborate on cancer research

Studies will aim to improve patient outcomes

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Cancer deaths in young people in UK drop by 58% in 40 years

Figures released by Cancer Research UK

- PMLiVE

MedImmune partners with US National Cancer Institute

Will research immunotherapies, imaging and stem cell treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links